Search alternatives:
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), nn decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i wt » _ wt (Expand Search), i w (Expand Search), i et (Expand Search)
Showing 1,501 - 1,520 results of 105,405 for search '(( i wt decrease ) OR ( 5 ((wt decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.45s Refine Results
  1. 1501
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 1502
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 1503
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 1504
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 1505
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 1506
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 1507
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 1508
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 1509
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 1510
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 1511
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 1512
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1513
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1514
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1515
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1516
    eIF5a is up-regulated in unruptured AAAs and decreased in ruptured AAAs.

    eIF5a is up-regulated in unruptured AAAs and decreased in ruptured AAAs. by Dong Ma (584680)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  17. 1517
    Loss of UPF proteins directly decreases the degradation of <i>cat-3</i> mRNA and indirectly increases <i>cat-3</i> gene transcription through elevating <i>cpc-1</i> mRNA stability.

    Loss of UPF proteins directly decreases the degradation of <i>cat-3</i> mRNA and indirectly increases <i>cat-3</i> gene transcription through elevating <i>cpc-1</i> mRNA stability. by Shuangjie Shen (12800414)

    Published 2023
    Save to List
    Saved in:
  18. 1518
    TachypleginA treatment causes a decrease in the motor activity of the TgMyoA motor complex.

    TachypleginA treatment causes a decrease in the motor activity of the TgMyoA motor complex. by Aoife T. Heaslip (207534)

    Published 2010
    Save to List
    Saved in:
  19. 1519
    The interaction of <i>F</i>. <i>tularensis</i> CipR and <i>kdsD</i>::<i>ltrB</i><sub><i>L1</i></sub> mutants with macrophage-like cells show a decrease in CFU recovery and disruption of the host monolayer.

    The interaction of <i>F</i>. <i>tularensis</i> CipR and <i>kdsD</i>::<i>ltrB</i><sub><i>L1</i></sub> mutants with macrophage-like cells show a decrease in CFU recovery and disrupti... by Taylor Chance (611108)

    Published 2017
    Save to List
    Saved in:
  20. 1520
    Resuscitation with AVP restores the mean arterial blood pressure.

    Resuscitation with AVP restores the mean arterial blood pressure. by Carrie A. Sims (4532332)

    Published 2017
    Save to List
    Saved in:

Search Tools: